Biomed Central Ltd

SHERPA: Unknown

People

  1. Budhu
    Budhu
  2. Cheung
    Cheung
  3. Postow
    Postow
  4. Shoushtari
    Shoushtari
  5. Shah
    Shah
  6. Voss
    Voss
  7. Aggen
    Aggen
  8. Aghajanian
    Aghajanian
  9. Autio
    Autio
  10. D'Angelo
    D'Angelo

Groups

  1. Department of Medicine (70)
  2. Solid Tumor Oncology Division (58)
  3. GSK Faculty (27)
  4. Hematologic Malignancies, Division of (24)
  5. Sloan Kettering Institute Postdocs (20)
  6. Melanoma and Immunotherapeutics Service (19)
  7. Hematology-Oncology Fellows (18)
  8. Weinberg Fellows (15)
  9. Center for Molecular Imaging and Biotechnology (CMIB) (14)
  10. Genitourinary Oncology Service (14)
Search Within
  1. "2021"
Formats
  1. Journal Article (48)
  2. Meeting Abstract (29)
  3. Review (6)
  4. Guidelines (4)
  5. Editorial (2)
  6. Research Letter (2)
Groups
  1. Department of Medicine (70)
  2. Solid Tumor Oncology Division (58)
  3. GSK Faculty (27)
  4. Hematologic Malignancies, Division of (24)
  5. Sloan Kettering Institute Postdocs (20)
  6. Melanoma and Immunotherapeutics Service (19)

More Groups

People
  1. Jedd Wolchok (10)
  2. Taha Merghoub (8)
  3. Matthew Hellmann (5)
  4. Alexander Shoushtari (4)
  5. Allison Betof Warner (4)
  6. Michael Postow (4)

More People

Years
  1. 2021 (91)
Publications
  1. Journal for ImmunoTherapy of Cancer (57)
  2. Journal of Hematology & Oncology (5)
  3. BMC Cancer (4)
  4. Cancer Imaging (2)
  5. Genome Biology (2)
  6. Genome Medicine (2)

More Publications

Results (91)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High quality neoantigens are immunoedited in long-term pancreatic cancer survivors
    Meeting Abstract

    Sethna, Z.; Luksza, M.; Rojas, L.; Soares, K.; Leung, J.; Lihm, J.; Hoyos, D.; Dobrin, A.; Kappagantula, R.; Makohon-Moore, A.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the phase 1b dose-escalation study
    Meeting Abstract

    Altan, M.; Patnaik, A.; Barve, M.; Dunn, L.; Cobb, P.; Rosenberg, A.; Sharma, S.; Sukari, A.; Patel, M.; Wang, X.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; George, M.; Venkatesh, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response
    Meeting Abstract

    Dong, L.; Choi, H.; Budhu, S.; Schulze, I.; Mehanna, N.; Rosen, N.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy
    Meeting Abstract

    Verma, S.; Maniyar, R.; Ko, M.; Budhu, S.; Serganova, I.; Zappasodi, R.; Blasberg, R.; Merghoub, T.; Wolchok, J.; Mangarin, L.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Single-cell RNA-seq reveals the critical roles of the sting- and MDA5-mediated cytosolic nucleic acid-sensing pathways as well as IFNAR/STAT2 signaling in recombinant MVA-induced antitumor immunity
    Meeting Abstract

    Liu, S.; Mazo, G.; Zhang, T.; Yang, N.; Wang, Y.; Tan, A.; Wang, J.; Choi, J.; Xiang, J. Z.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B.; Curti, B.; Hall, E.; Hansen, A.; Long, G.; Joshua, A.; Shankles, B.; Ulge, U.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
    Meeting Abstract

    Sacco, J.; Carvajal, R.; Butler, M.; Shoushtari, A.; Hassel, J.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers
    Meeting Abstract

    Budhu, S.; Gupta, A.; Fitzgerald, K.; Giese, R.; Michel, A.; Holland, A.; Campesato, L. F.; Van Snick, J.; Uyttenhove, C.; Ritter, G.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save